MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/go-26-00090

Медицинская библиотека · JCO global oncology · 2026

Outcomes of Adults Age 40 Years and Older With Newly Diagnosed ALL: A Multicenter Registry Analysis From the Hematology Cancer Consortium.

Jain Punit, Jain Hasmukh, Sarma Rup Jyoti, Kulkarni Uday, Karunakaran Parathan, Kayal Smita, Ganesan Prasanth, Lk Rajeev, Damodar Sharat, Kapoor Rajan, Palassery Rasmi, Krishnan Unni, Roshan Reshma, Chozakade Aakash, Asokan Abirami, Samuel Prasanna, Karunamurthy Omprakash, Mathews Vikram, Sengar Manju

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

PURPOSE: Outcomes in adults age 40 years and older with ALL are inferior to younger patients, with limited real-world data.

METHODS

This is a retrospective analysis of adults age 40 years and older with newly diagnosed ALL enrolled in the Hematology Cancer Consortium registry from January 2019 to January 2021. Baseline variables, treatment patterns, response rates, toxicities, and survival were assessed. Overall survival (OS) and event-free survival (EFS) were estimated using Kaplan-Meier methodology.

RESULTS

Of 349 registered patients, 61.3% (n = 214/349) initiated therapy, while 38.6% (n = 135/349) refused therapy. B-ALL represented 81% of cases (n = 174/214). Berlin-Frankfurt-Münster was used in 61.6% (n = 132/214) and German ALL in 30.3% (n = 65/214). Induction mortality was 18.6% (n = 40/214), mainly infection-related. Complete remission rates were 59.8% among assessed patients (n = 128/214), with minimal residual disease negativity in 45.8% (n = 61/133). Treatment de-escalation due to intolerance occurred in 30.8% (n = 66/214), and 35% (n = 75/214) were lost to follow-up. 3.7% (n = 8) patients underwent allotransplantation. At a median follow-up of 34 months, 3-year OS and EFS rates for the entire cohort were 31% and 29.6%, respectively (n = 214). Median OS and EFS were 13 and 11 months, respectively.

CONCLUSION

Adults age 40 years and older with ALL in India have poor outcomes, driven by early mortality, treatment intolerance, and limited access to advanced therapies.

Для цитирования: Jain Punit, Jain Hasmukh, Sarma Rup Jyoti, Kulkarni Uday, Karunakaran Parathan, Kayal Smita, Ganesan Prasanth, Lk Rajeev, Damodar Sharat, Kapoor Rajan, Palassery Rasmi, Krishnan Unni, Roshan Reshma, Chozakade Aakash, Asokan Abirami, Samuel Prasanna, Karunamurthy Omprakash, Mathews Vikram, Sengar Manju. Outcomes of Adults Age 40 Years and Older With Newly Diagnosed ALL: A Multicenter Registry Analysis From the Hematology Cancer Consortium.. JCO global oncology. 2026. DOI: 10.1200/go-26-00090.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.